FONT-SIZE Plus   Neg

Derma Sciences Buys Global Long-Term Exclusive Rights To NIMBUS Technology

Derma Sciences Inc. (DSCI) and Quick-Med Technologies Inc. reached an agreement, whereby Quick-Med Technologies has granted Derma Sciences an exclusive global license to intellectual property related to the novel NIMBUS antimicrobial technology, which is available in BIOGUARD dressings.

As per the deal, Derma Sciences would make a $1.3 million upfront payment to Quick-Med Technologies and future milestone payments based on sales of products incorporating the licensed technology. Further, the royalty paid by Derma Sciences to Quick-Med Technologies on such products would be lowered from 20% currently, to a sliding scale starting at 8.5% and declining as sales milestones are achieved.

Sales by Derma Sciences of products covered under this deal were some $1.5 million in 2011, and may grow between 30% and 40% annually, in line with view for the company's advanced wound care product portfolio.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Boeing Co. (BA) reported a profit for the third-quarter climbed 34 percent from the the previous year, reflecting overall solid execution on production programs and services, favorable tax items, and timing of aircraft deliveries. The company raised its 2016 financial and delivery guidance reflecting higher commercial deliveries and the impact of the tax basis adjustment. GlaxoSmithKline PLC (GSK.L, GSK) reported that its third-quarter core operating profit was 2.32 billion pounds, 13% higher in CER terms than in prior year. Core earnings per share for the quarter was up 12% CER to 32.0 pence. Total basic earnings per share was 16.6 pence, down 1% CER, primarily reflecting... Coca-Cola Co. (KO) reported a profit for the third-quarter that declined 28 percent from the prior year. Net revenues were down 7% from prior year, impacted by a foreign currency exchange headwind of 2% and a headwind from acquisitions, divestitures and structural items of 8%. The company reaffirmed organic revenue and comparable earnings per share outlook for fiscal year 2016.
comments powered by Disqus
Follow RTT